Equities

Shenzhen Chipscreen Biosciences Co Ltd

688321:SHH

Shenzhen Chipscreen Biosciences Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)21.58
  • Today's Change-0.21 / -0.96%
  • Shares traded1.93m
  • 1 Year change-7.50%
  • Beta--
Data delayed at least 15 minutes, as of May 28 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shenzhen Chipscreen Biosciences Co Ltd is a China-based company mainly engaged in the research and development of original innovative drugs. The Company focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The Company's main products include Chidamide, Siglitazone, Cioroni and CS12192. The Company mainly conducts its businesses in the domestic market.

  • Revenue in CNY (TTM)547.79m
  • Net income in CNY103.01m
  • Incorporated2001
  • Employees1.06k
  • Location
    Shenzhen Chipscreen Biosciences Co Ltd21F-24F, Building B, Zhigu Industrial Park, Shuguang CommunSHENZHEN 518057ChinaCHN
  • Phone+86 75 526952070
  • Fax+86 75 526957291
  • Websitehttps://www.chipscreen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vcanbio Cell & Gene Engineering Corp Ltd1.61bn109.23m8.40bn2.21k76.942.28--5.220.23340.23343.447.880.30342.012.86728,818.101.971.132.791.6167.9767.766.513.841.526.930.02840.002.243.78-5.7812.43-7.11--
North China Pharmaceutical Co Ltd10.02bn17.62m8.51bn10.16k482.961.60--0.84950.01030.01035.843.110.46932.714.31986,082.900.3543-0.29780.8122-0.704230.2635.730.755-0.59850.54251.430.6473---3.621.89100.71-49.624.22-19.73
Shenzhen Chipscreen Biosciences Co Ltd547.79m103.01m8.96bn1.06k84.535.26--16.360.25780.25781.334.150.17611.663.97518,248.702.141.322.611.5486.9993.2912.176.972.99--0.40370.00-1.1828.81408.0923.3110.23--
Nanjing Vazyme Biotech Co Ltd1.29bn-15.12m9.20bn2.70k--2.28--7.16-0.0368-0.03683.2710.070.21910.97612.85476,061.10-0.28613.16-0.372415.9271.3170.50-1.3123.922.97--0.215432.20-63.9749.74-111.94--48.61--
Aurisco Pharmaceutical Co Ltd1.30bn325.73m9.22bn1.52k28.264.43--7.110.8030.8033.185.120.54041.174.99852,082.9013.5712.4016.4614.3356.9051.2625.1223.051.72--0.11625.1525.2417.0237.2316.1626.54--
China Animal Husbandry Industry Co., Ltd5.47bn339.08m9.33bn4.33k27.531.67--1.710.33210.33215.365.480.63314.134.891,264,384.003.336.234.719.0118.9524.295.268.691.86--0.201731.20-8.244.04-26.73-0.612724.20-3.77
Zhejiang Hisun Pharmaceutical Co., Ltd.10.04bn-76.94m9.59bn8.06k--1.16--0.9556-0.0823-0.08238.456.860.55353.324.531,244,871.00-0.50841.95-0.85693.7738.3540.58-0.91873.430.6303--0.415826.07-13.820.3618-119.05---31.58--
Data as of May 28 2024. Currency figures normalised to Shenzhen Chipscreen Biosciences Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

3.48%Per cent of shares held by top holders
HolderShares% Held
Bosera Asset Management Co., Ltd.as of 31 Dec 20233.54m0.86%
Penghua Fund Management Co., Ltd.as of 31 Dec 20233.17m0.77%
Da Cheng Fund Management Co., Ltd.as of 31 Dec 20231.84m0.45%
The Vanguard Group, Inc.as of 09 May 20241.25m0.30%
China Asset Management Co., Ltd.as of 31 Dec 20231.20m0.29%
China Universal Asset Management Co., Ltd.as of 31 Dec 20231.06m0.26%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023951.56k0.23%
China Southern Asset Management Co., Ltd.as of 30 Jun 2023476.51k0.12%
AXA-SPDB Investment Managers Co., Ltd.as of 31 Dec 2023416.33k0.10%
E Fund Management Co., Ltd.as of 31 Dec 2023399.60k0.10%
More ▼
Data from 31 Dec 2023 - 22 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.